

**Amendment to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**In the claims:**

Claims 1-14 (Canceled)

Claim 15 (Withdrawn-Currently Amended) The composition of claim 32 [[4]], wherein at least two of the antigens (1) to (5) are expressed as a single polypeptide chain.

Claim 16 (Withdrawn-Currently Amended) The composition of claim 15 [[4]], wherein the two recombinant polypeptides are at least two of the antigens expressed as a single polypeptide chain and are selected from the group of antigens consisting of: the first antigen a 'NadA' protein & the second antigen a 'NMB1870' protein; the first antigen the 'NadA' protein & the third antigen a 'NMB2091' protein; the first antigen the 'NadA' protein & the fourth antigen a 'NMB1030' protein; the first antigen the 'NadA' protein & the fifth antigen a 'NMB2132' protein; the second antigen the 'NMB1870' protein & the third antigen the 'NMB2091' protein; the second antigen the 'NMB1870' protein & the fourth antigen the 'NMB1030' protein; the second antigen the 'NMB1870' protein & the fifth antigen the 'NMB2132' protein; the third antigen the 'NMB2091' protein & the fourth antigen the 'NMB1030' protein; the third antigen the 'NMB2091' protein & the fifth antigen the 'NMB2132' protein; the fourth antigen the 'NMB1030' protein & the fifth antigen the 'NMB2132' protein.

Claim 17 (Withdrawn-Currently Amended) The composition of claims 15 or 16, wherein the single polypeptide chain comprises a polypeptide of formula NH<sub>2</sub>-A-X<sub>1</sub>-L-X<sub>2</sub>-B-COOH, wherein: X<sub>1</sub> is an amino acid sequence of one of the five antigens selected from the group consisting of the first antigen the 'NadA' protein, the second antigen the 'NMB1870' protein; the third antigen the 'NMB2091' protein; the fourth antigen the 'NMB1030' protein; and the fifth antigen the 'NMB2132' protein; X<sub>2</sub> is an amino acid sequence of one of the five antigens selected from the group consisting of

of the first antigen the 'NadA' protein, the second antigen the 'NMB1870' protein; the third antigen the 'NMB2091' protein; the fourth antigen the 'NMB1030' protein; and the fifth antigen the 'NMB2132' protein provided that X<sub>1</sub> is not the same as X<sub>2</sub>; L is an optional linker amino acid sequence; A is an optional N-terminal amino acid sequence; and B is an optional C-terminal amino acid sequence.

Claim 18 (Withdrawn-Currently Amended) The composition of claim 17, wherein X<sub>1</sub> is the third antigen the NMB2091 protein and X<sub>2</sub> is the second antigen the NMB1870 protein.

Claim 19 (Withdrawn-Currently Amended) The composition of claim 17, wherein X<sub>1</sub> is the fifth antigen the NMB2132 protein and X<sub>2</sub> is the fourth antigen the NMB1030 protein.

Claims 20-21 (Canceled).

Claim 22 (Withdrawn-Currently Amended) The composition of claim 32 [[4]], further comprising saccharide antigens from meningococcus serogroups Y, W135, C and (optionally) A.

Claim 23 (Withdrawn-Currently Amended) The composition of claim 32 [[4]], further comprising a saccharide antigen from *Haemophilus influenzae* type B.

Claim 24 (Withdrawn) The composition of claim 22 or claim 23, wherein the saccharide antigen is conjugated to a carrier selected from: diphtheria toxoid, tetanus toxoid, CRM<sub>197</sub> or *H.influenzae* protein D.

Claim 25 (Withdrawn-Currently Amended) The composition of claim 32 [[4]], further comprising an antigen from *Streptococcus pneumoniae*.

Claim 26 (Currently Amended) The composition of claim 32 [[4]] further comprising a pharmaceutically acceptable carrier.

Claim 27 (Canceled).

Claim 28 (Withdrawn-Currently Amended) A method for raising an antibody response in a mammal, comprising the step of administering an effective amount of a composition according to any one of claims 32 [[4]], 15, or 16.

Claims 29-31 (Canceled).

Claim 32 (Currently Amended) [[The]] A composition comprising five meningococcal antigens of claim 4, wherein the first antigen NadA protein comprises an amino acid sequence having at least 90% sequence identity to SEQ ID 2, wherein the second antigen NMB1870 protein comprises an amino acid sequence having at least 90% sequence identity to SEQ ID 3, wherein the third antigen NMB2091 protein comprises an amino acid sequence having at least 90% sequence identity to SEQ ID 4, wherein the fourth antigen NMB1030 protein comprises an amino acid sequence having at least 90% sequence identity to SEQ ID 5, and wherein the fifth antigen NMB2132 protein comprises an amino acid sequence having at least 90% sequence identity to SEQ ID 6.

Claim 33 (Currently Amended) The composition of claim 32 [[4]], wherein the first antigen NadA protein comprises an amino acid sequence having at least 95% sequence identity to SEQ ID 2, wherein the second antigen NMB1870 protein comprises an amino acid sequence having at least 95% sequence identity to SEQ ID 3, and wherein the third antigen NMB2091 protein comprises an amino acid sequence having at least 95% sequence identity to SEQ ID 4, wherein the fourth antigen NMB1030 protein comprises an amino acid sequence having at least 95% sequence identity to SEQ ID 5, and wherein the fifth antigen NMB2132 protein comprises an amino acid sequence having at least 95% sequence identity to SEQ ID 6.

Claim 34 (Currently Amended) The composition of claim 33 [[4]], wherein the NadA protein comprises SEQ ID 2, wherein the second antigen NMB1870 protein comprises SEQ ID 3, and wherein the third antigen NMB2091 protein comprises SEQ ID 4, wherein the fourth antigen NMB1030 protein comprises SEQ ID 5, and wherein the fifth antigen NMB2132 protein comprises SEQ ID 6.

Claim 35 (New) The composition of claim 33, wherein the first antigen comprises an amino acid sequence having at least 99% sequence identity to SEQ ID 2, wherein the second antigen comprises an amino acid sequence having at least 99% sequence identity to SEQ ID 3, and wherein the third antigen comprises an amino acid sequence having at least 99% sequence identity to SEQ ID 4, wherein the fourth antigen comprises an amino acid sequence having at least 99% sequence identity to SEQ ID 5, and wherein the fifth antigen comprises an amino acid sequence having at least 99% sequence identity to SEQ ID 6.

Claim 36 (New) The composition of claim 32, wherein the third antigen and the second antigen are expressed as a first single polypeptide where the second antigen is fused to the C-terminus of the third antigen optionally through a first linker amino acid sequence, and wherein the fifth antigen and the fourth antigen are expressed as a second single polypeptide where the fourth antigen is fused to the C-terminus of the fifth antigen optionally through a second linker amino acid sequence.

Claim 37 (New) The composition of claim 33, wherein the third antigen and the second antigen are expressed as a first single polypeptide where the second antigen is fused to the C-terminus of the third antigen optionally through a first linker amino acid sequence, and wherein the fifth antigen and the fourth antigen are expressed as a second single polypeptide where the fourth antigen is fused to the C-terminus of the fifth antigen optionally through a second linker amino acid sequence.

Claim 38 (New) The composition of claim 34, wherein the third antigen and the second antigen are expressed as a first single polypeptide where the second antigen is fused to the C-terminus of the third antigen optionally through a first linker amino acid sequence, and wherein the fifth antigen and the fourth antigen are expressed as a second single polypeptide where the fourth antigen is fused to the C-terminus of the fifth antigen optionally through a second linker amino acid sequence.

Claim 39 (New) The composition of claim 35, wherein the third antigen and the second antigen are expressed as a first single polypeptide where the second antigen is fused to the C-terminus of the third antigen optionally through a first linker amino acid sequence, and wherein the fifth antigen and

the fourth antigen are expressed as a second single polypeptide where the fourth antigen is fused to the C-terminus of the fifth antigen optionally through a second linker amino acid sequence.